TY  - JOUR
T1  - Effective treatment of traumatic brain injury: Learning from experience
AU  - Ruff RL, Riechers RG
Y1  - 2012/11/21
N1  - 10.1001/jama.2012.14008
JO  - JAMA
SP  - 2032
EP  - 2033
VL  - 308
IS  - 19
N2  - 
In this issue of JAMA, Zafonte and colleagues1 present the findings of the Citicoline Brain Injury Treatment Trial (COBRIT), a phase 3, double-blind study comparing citicoline vs placebo. In this trial, 1213 study participants with complicated mild, moderate, or severe traumatic brain injury (TBI) were randomized to receive 2000 mg of citicoline or placebo daily for 90 days. The study, which did not demonstrate any benefits of citicholine treatment, is likely to have implications not only for the use of citicoline in patients with TBI but also for the design of future trials of TBI therapies.

SN  - 0098-7484
M3  - doi: 10.1001/jama.2012.14008
UR  - http://dx.doi.org/10.1001/jama.2012.14008
ER  -